SAINT-CLOUD, France--(BUSINESS WIRE)--Ethypharm are pleased to announce that they have acquired 100% of the share capital of DBA Group (DBA), a branded pharmaceutical business established in the UK in 2009.
DBA currently markets and supplies a range of prescription only medicines to the UK market, generating significant savings for the National Health Service (NHS) and has an exciting pipeline of products in development which will be supplemented with a wide range of additional products from the Ethypharm pipeline.
Through the acquisition of DBA, Ethypharm continues to implement its strategy to develop a direct commercial presence in key territories in Europe to market Central Nervous System products, with a particular focus on pain and innovative treatments for addiction. DBA provides a pivotal platform to generate revenues in the important UK market and this acquisition along with the deployment of its own commercial operations in France and Germany, will generate a turnover of more than € 240 million for Ethypharm.
“I am delighted to welcome the DBA team to the Ethypharm group. The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic and DBA offers a great platform to launch products from our own pipeline,” declared Hugues Lecat, CEO of Ethypharm.
About Ethypharm
Ethypharm is an independent pharmaceutical company with global reach. It is dedicated to developing innovative drugs to treat pain and addiction, two major therapeutic areas with large unmet medical needs. Ethypharm also develops complex generics that contribute towards optimization of healthcare costs. Ethypharm employs 900 people, mostly in France where its innovation center is based as well as two high quality manufacturing sites. Ethypharm drugs are currently marketed in 30 different countries around the world.
Visit our new website at www.ethypharm.com
